Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2009

View Archived Issues

Karo Bio present update on drug development programs

Dienogest exhibits favorable safety profile in the long-term treatment of endometriosis

Phase I study results encourage further development of anesthetic PF-0713

EMEA committee informs Antigenics of negative opinion on MAA for Oncophage in RCC

Gilead reports results from third quarter of 2009

PSN-0041 displays enhanced antidepressant activity over native amylin in preclinical tests

Preclinical characterization of SEP-230864 presented by Sepracor

KB-099520 increases serotonergic activity and demonstrates antidepressant effects

IMO-3100 active in arthritis model, intended for clinical development

Naproxcinod efficacy similar to naproxen in knee osteoarthritis patients

Brain autoimmune mechanisms implicated in the pathogenesis of OCD / News in Context

Peregrine reports positive tumor response rate in phase II bavituximab trial

Aerie reports phase IIa results for ROCK inhibitor, AR-12286, in glaucoma

AcelRx presents results from phase II ARX-03 study

KemPharm commences phase I KP-106 trial in ADHD

Roche doses first patient in phase III subcutaneous Herceptin trial

TargeGen completes TG-101348 trial in patients with myelofibrosis

NexGenix awarded phase I grant for small-molecule Hsp90 compounds for glioma

Repligen licenses compounds for potential spinal muscular atrophy treatment

Merck and Schering-Plough receive European Commission clearance for merger

Aeolus drug protects gastrointestinal tract in acute radiation syndrome studies

CHMP recommends Boehringer's Micardis for CV morbidity in high CV risk patients

Onyx and Bayer initiate phase III trial of Nexavar in nonresponsive thyroid cancer

Pharmaxis commences pivotal bronchiectasis study with Bronchitol

CGRP antagonists for the treatment of migraine claimed by Merck & Co.

New glucokinase activators described by Astellas Pharma as antidiabetic agents

GlaxoSmithKline presents antiviral compounds for HCV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...